Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although it has long been appreciated that ovarian carcinoma subtypes (serous, clear cell, endometrioid, and mucinous) are associated with different natural histories, most ovarian carcinoma biomarker studies and current treatment protocols for women with this disease are not subtype specific. With the emergence of high-throughput molecular techniques, distinct pathogenetic pathways have been identified in these subtypes. We examined variation in biomarker expression rates between subtypes, and how this influences correlations between biomarker expression and stage at diagnosis or prognosis. METHODS AND FINDINGS: In this retrospective study we assessed the protein expression of 21 candidate tissue-based biomarkers (CA125, CRABP-II, EpCam, ER, F-Spondin, HE4, IGF2, K-Cadherin, Ki-67, KISS1, Matriptase, Mesothelin, MIF, MMP7, p21, p53, PAX8, PR, SLPI, TROP2, WT1) in a population-based cohort of 500 ovarian carcinomas that was collected over the period from 1984 to 2000. The expression of 20 of the 21 biomarkers differs significantly between subtypes, but does not vary across stage within each subtype. Survival analyses show that nine of the 21 biomarkers are prognostic indicators in the entire cohort but when analyzed by subtype only three remain prognostic indicators in the high-grade serous and none in the clear cell subtype. For example, tumor proliferation, as assessed by Ki-67 staining, varies markedly between different subtypes and is an unfavourable prognostic marker in the entire cohort (risk ratio [RR] 1.7, 95% confidence interval [CI] 1.2%-2.4%) but is not of prognostic significance within any subtype. Prognostic associations can even show an inverse correlation within the entire cohort, when compared to a specific subtype. For example, WT1 is more frequently expressed in high-grade serous carcinomas, an aggressive subtype, and is an unfavourable prognostic marker within the entire cohort of ovarian carcinomas (RR 1.7, 95% CI 1.2%-2.3%), but is a favourable prognostic marker within the high-grade serous subtype (RR 0.5, 95% CI 0.3%-0.8%). CONCLUSIONS: The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different diseases, and these differences should be reflected in clinical research study design and ultimately in the management of ovarian carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8].”
BackgroundWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040 · cited 1×
“, breast carcinoma and lymphoma [24,25]), and this subtype specific approach to treatment has implications for the design of clinical trials for women with ovarian carcinomas.”
BackgroundGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670 · cited 1×
“The serous subtype was further subdivided into low- and high-grade [11].”
BackgroundLu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440 · cited 1×
“For example, CA125 is expressed in most high-grade serous carcinoma, but only in 60% of mucinous and clear cell subtypes, a finding that is consistent with previous studies [26].”
ResultSchwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408 · cited 1×
“The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [”
MethodZorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376 · cited 1×
“Each of theses subtypes is associated with different genetic risk factors and molecular events during oncogenesis [1,2], and characterized by distinct mRNA expression profiles [3,4].”
Background
Research works printed but not linked: 2
- Swenerton KD 2008 Ovarian carcinoma treatment guidelines of the British Columbia Cancer Agency Available: http://www.bccancer.bc.ca/PPI/TypesofCancer/Ovary/default.htm. Accessed 1 April 2000
- Turbin DA Leung S 2008 GPEC plugin for Image J an image analyzing software Available: http://www.gpec.ubc.ca/index.php?content=software/imagej_plugin/index.php. Accessed 20 April 2008
Cited by
Items 201–300 of 895
Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation
Coelho, R., Ricardo, S. A. V., Amaral, A. L., Huang, Y., Nunes, M., Neves, J. P., Mendes, N. M., López, M. N., Bartosch, C., Ferreira, V., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-00246-2 · Cited by 64
Antunovic, L., Cimitan, M., Borsatti, E., Baresic, T., Sorio, R., Giorda, G., Steffan, A., Balestreri, L., Tatta, R., Pepe, G., et al. (2012) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31825b2583 · Cited by 63
“Different histological types of ovarian cancer seem to be associated to distinct genetic risk factors that may influence the disease stage at the moment of diagnosis and the tumor response to chemotherapy; clear cells and mucinous subtypes of ovarian tumor showed poor response to platinum-based chemotherapy and these…”
BackgroundThe emerging role of CXC chemokines in epithelial ovarian cancer
Rainczuk, A., Rao, J., Gathercole, J. L., & Stephens, A. N. (2012) · Reproduction · doi:10.1530/rep-12-0153 · Cited by 65
“EOCs are commonly classified according to histopathological appearance as clear cell, endometrioid, mucinous or serous; amongst these, serous epithelial tumours are the most commonly diagnosed tumour type (Kobel et al. 2008).”
BackgroundDrabovich, A. P., & Diamandis, E. P. (2010) · Journal of Proteome Research · doi:10.1021/pr900729g · Cited by 60
Mueller, J. J., Schlappe, B. A., Kumar, R., Olvera, N., Dao, F., Abu‐Rustum, N. R., Aghajanian, C. A., DeLair, D. F., Hussein, Y. R., Soslow, R. A., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.05.008 · Cited by 63
“Unilateral tumor size ≥10cm and expression of CK7 with or without CK20 expression were used to confirm the diagnosis of primary MOC along with normal upper and lower endoscopy and prolonged clinical follow-up without evidence of gastrointestinal involvement in patients with advanced stage disease, and the absence of t…”
MethodSpowart, J. E., Townsend, K. N., Huwait, H., Eshragh, S., West, N. R., Ries, J., Kalloger, S. E., Anglesio, M. S., Gorski, S. M., Watson, P. H., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4090 · Cited by 62
Self-citationCipollone, J., Graves, M. L., Köbel, M., Kalloger, S. E., Poon, T. K. C., Gilks, C. B., McNagny, K. M., & Roskelley, C. D. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9446-0 · Cited by 62
“consisting of 500 EOC [27, 28] and were able to confidently score a total of 479 cases for the absence or presence of podocalyxin (Table 1).”
Self-citationFunctional Role and Prognostic Significance of CD157 in Ovarian Carcinoma
Ortolan, E., Arisio, R., Morone, S., Bovino, P., Buono, N. L., Nacci, G., Parrotta, R., Katsaros, D., Rapa, I., Migliaretti, G., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq256 · Cited by 62
“This is primarily a consequence of our current inability to detect tumors at an early stage (2); most patients are diagnosed at an advanced stage of disease when cancer has spread throughout the peritoneum.”
Cobb, L. P., Sun, C. C., Iyer, R. B., Nick, A. M., Fleming, N. D., Westin, S. N., Sood, A. K., Wong, K., Silva, E. G., & Gershenson, D. M. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.06.498 · Cited by 61
Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients
Chen, Y. J., Chen, C., Twu, N.-F., Yen, M., Lai, C., Wu, H., Wang, P.-H., & Yuan, C.-C. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0838-3 · Cited by 61
Motohara, T., Yoshida, G. J., & Katabuchi, H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.038 · Cited by 60
Sallum, L. F., Andrade, L. A. L. D. A., Ramalho, S., Ferracini, A. C., Natal, R. D. A., Brito, A. B. C., Sarian, L. O., & Derchain, S. (2018) · Oncotarget · doi:10.18632/oncotarget.24530 · Cited by 60
Bose, S., Saha, P., Chatterjee, B., & Srivastava, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.028 · Cited by 59
Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data
Zhang, Z., Huang, K., Gu, C., Zhao, L., Wang, N., Wang, X., Zhao, D., Zhang, C., Lu, Y., & Meng, Y. (2016) · Scientific Reports · doi:10.1038/srep26001 · Cited by 51
Li, M., Li, H., Liu, F., Bi, R., Tu, X., Chen, L., Ye, S., & Cheng, X. (2017) · Journal of Ovarian Research · doi:10.1186/s13048-017-0304-9 · Cited by 59
“Background The histological types of epithelial ovarian carcinoma (EOC) have distinct clinical and molecular features with each other [1, 2].”
BackgroundSuppression of REV 7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells
Niimi, K., Murakumo, Y., Watanabe, N., Kato, T., Mii, S., Enomoto, A., Asai, M., Asai, N., Yamamoto, E., Kajiyama, H., et al. (2014) · Cancer Science · doi:10.1111/cas.12390 · Cited by 59
Wei, J., Wu, J., Luan, C., Yeldandi, A. V., Lee, P., Keh, P. C., & Liu, J. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181be5d72 · Cited by 58
“1), consistent with previously reported studies.(11) P53 immunoreactivity was occasionally seen in normal fallopian tubes (Fig.”
ResultArora, N., Talhouk, A., McAlpine, J. N., Law, M. R., & Hanley, G. E. (2018) · BMC Cancer · doi:10.1186/s12885-018-4970-9 · Cited by 58
Seidman, J. D., Yemelyanova, A. V., Cosin, J. A., Smith, A. Y., & Kurman, R. J. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31823c6f80 · Cited by 58
Gabrielson, M., Björklund, M., Carlson, J. W., & Shoshan, M. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107109 · Cited by 58
“The EOC subtypes express ERa at different levels, and expression is lowest in CCC [26].”
BackgroundResultRGD cadherins and α2β1 integrin in cancer metastasis: A dangerous liaison
Casal, J. I., & Bartolomé, R. A. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.005 · Cited by 57
“It has been implicated in kidney carcinoma [52, 78, 79], ovarian carcinoma [80, 81], thyroid cancers [82, 83], cholangiocarcinoma [84], hepatocellular and small cell lung carcinoma [85], sometimes as pro-metastatic protein and sometimes as suppressor (Table 1).”
BackgroundXue, H., Wang, Y. Z., MacCormack, T. J., Lutes, T., Rice, C., Davey, M., Dugourd, D., Ilenchuk, T. T., & Stewart, J. M. (2018) · Journal of Cancer · doi:10.7150/jca.20639 · Cited by 57
“We present here the comparative expression of TRPV6 gene in biopsies of all five types [43] of ovarian cancers.”
BackgroundCHIEN, J. R., Sicotte, H., Fan, J., Humphray, S., Cunningham, J. M., Kalli, K. R., Oberg, A. L., Hart, S. N., Li, Y., Davila, J. I., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv111 · Cited by 56
“that early and late stage HGS carcinomas are indistinguishable based on immunohistochemical analysis 21 biomarkers (54), extend these findings to the whole-genome level.”
BackgroundTang, H., Beer, L. A., Chang-Wong, T., Hammond, R., Gimotty, P. A., Coukos, G., & Speicher, D. W. (2011) · Journal of Proteome Research · doi:10.1021/pr200603h · Cited by 57
Mucinous ovarian cancer: A therapeutic review
Xu, W., Rush, J., Rickett, K., & Coward, J. I. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.015 · Cited by 56
“nature of this disease and the necessity for each sub-type to be handled as separate disease entities, with unique prognostic and therapeutic paradigms [33].”
Bialucha, C. U., Collins, S. D., Li, X., Saxena, P., Zhang, X., Dürr, C., Lafont, B., Prieur, P., Shim, Y., Mosher, R. E., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1414 · Cited by 56
Chen, S., Dai, X., Gao, Y., Shen, F., Ding, J., & Chen, Q. (2017) · Scientific Reports · doi:10.1038/s41598-017-17265-6 · Cited by 56
Parra‐Herran, C., Bassiouny, D., Lerner‐Ellis, J. P., Olkhov‐Mitsel, E., Ismiil, N. D., Hogen, L. F., Vicus, D., & Nofech‐Mozes, S. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001328 · Cited by 56
Tacha, D., Qi, W., Zhou, D., Bremer, R. E., & Liang Cheng, C. (2012) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e318257cc1c · Cited by 56
Zhang, M., Liu, G., Xue, F., Edwards, R. P., Sood, A. K., Zhang, W., & Yang, D. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.01.004 · Cited by 55
“OvCa is clinically and pathologically heterogeneous with different subtypes and etiologies [1].”
BackgroundWT1 Expression in the Female Genital Tract
Bárcena, C., & Oliva, E. (2011) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e318234aaed · Cited by 55
“3), calretinin, CK5/6, and D2-40 are positive in more than 90% of mesotheliomas(97); however, they may also be expressed in approximately 90%, 10%, 25% and 65% of OSC, respectively.(94) WT1 positivity in mesothelioma has been reported to range from 43% to 90% 97–100 but it is also positive in the vast majority high-gr…”
BackgroundUpdate on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer
Gourley, C., Walker, J. L., & MacKay, H. J. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158927 · Cited by 55
Heckl, M., Schmoeckel, E., Hertlein, L., Rottmann, M., Jeschke, U., & Mayr, D. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192881 · Cited by 55
Clear cell carcinomas of the ovary and kidney: clarity through genomics
Ji, J. X. Y., Wang, Y. K., Cochrane, D. R., & Huntsman, D. D. (2018) · The Journal of Pathology · doi:10.1002/path.5037 · Cited by 55
“Clear cell ovarian cancer (CCOC) is a distinct entity within the EOCs [2], and accounts for 5–11% of cases of EOC in North America and 24.8% in Japan [3].”
BackgroundInfluentialSelf-citationThe Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Cheng, Z., Mirza, H., Ennis, D. P., Smith, P., Gavarró, L. M., Sokota, C., Giannone, G., Goranova, T., Bradley, T., Piskorz, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1643 · Cited by 55
“Together, the SNV/indel and focal CNA data corroborate fi ndings by K € obel and colleagues that early-stage and late-stage HGSC appear identical by IHC (33).”
Cytokine gene expression signature in ovarian clear cell carcinoma
Yanaihara, N., Anglesio, M. S., Ochiai, K., Hirata, Y., Saito, M., Nagata, C., Iida, Y., Takakura, S., Yamada, K., Tanaka, T., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1533 · Cited by 55
“Serous cancers seem to initially respond well to platinum and taxane chemotherapy, whereas other subtypes respond poorly or not at all (2-5).”
Nodin, B., Zendehrokh, N., Brändstedt, J., Nilsson, E., Manjer, J., Brennan, D. J., & Jirström, K. (2010) · Journal of Ovarian Research · doi:10.1186/1757-2215-3-14 · Cited by 54
Chan, A. M. Y., Enwere, E. K., McIntyre, J. B., Wilson, H., Nwaroh, C., Wiebe, N. J. P., Ou, Y., Liu, S., Wiedemeyer, K., Rambau, P., et al. (2020) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.168 · Cited by 54
Self-citationΔ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
Hofstetter, G., Berger, A., Schuster, E., Wolf, A. M., Hager, G., Vergote, I. B., Cadron, I., Sehouli, J., Braicu, E. I., Mahner, S., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.433 · Cited by 54
“For instance, serous carcinomas show WT1, Mesothelin, oestrogen receptor and CA125 expression in 475%, while the mucinous subtype displays frequent expression of Matriptase, and endometrioid carcinomas express high rates of estrogen and progesterone receptor and CA125 (Köbel et al, 2008).”
BackgroundVallen, M. J. E., Massuger, L. F. A. G., ten Dam, G. B., Bulten, J., & Kuppevelt, T. H. V. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.06.022 · Cited by 54
“We relatedGD3G7 epitope expression to prognostic parameters and survival, and compared the data with biomarkers p53 and Ki-67 [16–20].”
MethodNameki, R. A., Chang, H. S. Y., Reddy, J., Corona, R. I., & Lawrenson, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107722 · Cited by 53
Kang, E., Weir, A. L., Meagher, N. S., Farrington, K., Nelson, G. S., Ghatage, P., Lee, C., Riggan, M. J., Bolithon, A., Popovic, G. C., et al. (2022) · Cancer · doi:10.1002/cncr.34582 · Cited by 53
Self-citationThe role of microRNAs in ovarian cancer initiation and progression
Li, S., Zhang, J., Wang, Y., & Wan, X. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01058.x · Cited by 53
Prognostic biomarkers in endometrial and ovarian carcinoma
Matías‐Guiu, X., & Davidson, B. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1509-y · Cited by 53
Morales-Vásquez, F., Pedernera, E. A., Obregón, J. R., López-Basave, H. N., Gómora, M. J., Carlón, E., Cárdenas, S., Silva-Ayala, R., Almaraz, M. Á., & Méndez, C. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0247-6 · Cited by 53
“Interestingly, a previous study of survival related to WT1 expression in EOC evidenced contrasting changes in the results, considering the entire cohort versus high grade serous subtype in Kaplan-Meier analysis [12].”
ResultHigh-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases
Assem, H., Rambau, P., Lee, S., Ogilvie, T., Sienko, A. E., Kelemen, L. E., & Köbel, M. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001016 · Cited by 53
Self-citationTakenaka, M., Köbel, M., Garsed, D. W., Fereday, S., Pandey, A., Etemadmoghadam, D., Hendley, J., Kawabata, A., Noguchi, D., Yanaihara, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3691 · Cited by 53
Self-citationLi, Y. L., Ye, F., Cheng, X. D., Hu, Y., Zhou, C. Y., Lu, W., & Xie, X. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.015 · Cited by 53
Molecular Management of High-Grade Serous Ovarian Carcinoma
Punzón-Jiménez, P., Lago, V., Domingo, S., Simón, C., & Mas, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213777 · Cited by 51
“Initial studies found elevated levels of CA125—a transmembrane cell-surface protein encoded by the MUC16 gene—in HGSOC compared to healthy ovarian tissue [26,27].”
BackgroundCurrent clinical use of biomarkers for epithelial ovarian cancer
Moore, R. G., & MacLaughlan, S. D. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833c3351 · Cited by 51
The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer
Tamir, A., Gangadharan, A., Balwani, S., Tanaka, T., Patel, U. J., Hassan, A. M., Benke, S., Agas, A., D’Agostino, J., Shin, D., et al. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0228-9 · Cited by 51
“Survival analyses on a large cohort of OVC showed that only 1 of 3 potential OVC prognostic biomarkers was meaningful with respect to specific OVC subtypes [29].”
APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner
Yi, Y., Tsai, S., Cheng, J., Wang, E. Y., Anglesio, M. S., Cochrane, D. R., Fuller, M., Gibb, E. A., Wei, W., Huntsman, D. D., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.10.016 · Cited by 51
Self-citationArthur, R., Kirsh, V. A., Kreiger, N., & Rohan, T. E. (2018) · Cancer Causes & Control · doi:10.1007/s10552-018-1032-1 · Cited by 51
Dieters‐Castator, D. Z., Rambau, P., Kelemen, L. E., Siegers, G. M., Lajoie, G., Postovit, L.-M. M., & Köbel, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3818 · Cited by 51
Self-citationThe N-Terminally Truncated p53 Isoform △40p53 Influences Prognosis in Mucinous Ovarian Cancer
Hofstetter, G., Berger, A., Berger, R., Zorić, A., Braicu, E. I., Reimer, D., Fiegl, H., Marth, C., Zeimet, A. G., Ulmer, H., et al. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31823ca031 · Cited by 51
“%) contrasts sharply with that of high-grade serous carcinomas (80%).6 These different clinical characteristics are accompanied by distinct biomarker expression profiles.7 For instance, serous carcinomas show WT1, mesothelin, estrogen receptor, and CA-125 expression in greater than 75%, whereas the mucinous subtype di…”
BackgroundLundin, E., Dossus, L., Clendenen, T. V., Krogh, V., Grankvist, K., Wulff, M., Sieri, S., Arslan, A. A., Lenner, P., Berrino, F., et al. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9330-2 · Cited by 51
“Our results suggest that CRP may be particularly relevant for mucinous tumors, a small sub-type of epithelial ovarian tumors (about 10% of invasive cancers), which differ substantially in terms of epidemiological, pathological, molecular, and clinical characteristics from the other subtypes [35].”
Rainczuk, A., Rao, J., Gathercole, J. L., Fairweather, N., Chu, S., Masadah, R., Jobling, T. W., Deb‐Choudhury, S., Dyer, J. M., & Stephens, A. N. (2013) · International Journal of Cancer · doi:10.1002/ijc.28393 · Cited by 50
Vidmar, T., Pavšič, M., & Lenar≷cic̆, B. (2013) · Protein Expression and Purification · doi:10.1016/j.pep.2013.07.006 · Cited by 50
Fogg, K. C., Olson, W. R., Miller, J. N., Khan, A., Renner, C. M., Hale, I., Weisman, P. S., & Kreeger, P. K. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.029 · Cited by 50
Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma
Llauradó, M., Dawson, A., Kim, H. H., Lam, N., Russell, H., Bruce, M., Bittner, M., Hoenisch, J., Scott, S., Talhouk, A., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.029 · Cited by 50
Self-citationNapsin A as a marker of clear cell ovarian carcinoma
Skírnisdóttir, I., Bjersand, K., Åkerud, H., & Seidal, T. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-524 · Cited by 49
“Thus, all markers were dichotomized into negative and positive groups [23].”
BackgroundSerum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer
Kong, S., Han, M. H., Yoo, H. J., Hwang, J. H., Lim, M. C., Seo, S., Yoo, C.-W., Kim, J., Park, S., & Kang, S. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1943-5 · Cited by 49
Beltran, P. J., Calzone, F. J., Mitchell, P., Chung, Y.-A., Cajulis, E. E., Moody, G. E., Belmontes, B., Li, C.-M., Vonderfecht, S. L., Velculescu, V. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3448 · Cited by 49
“been identified in ovarian cancer that may also aid in the future selection of patients that likely benefit from IGF-IR inhibition (35, 36).”
BackgroundRole of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer
Lee, S., Choi, S., Lee, Y., Chung, D., Hong, S., & Park, N.-H. (2016) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13181 · Cited by 49
“HE4 expressionwas not an independent prognostic factor in one study when dichotomized according to negative and positive.(25) Problematically, early stage ovarian cancer patients comprised 83.”
BackgroundRambau, P., Kelemen, L. E., Steed, H. L., Quan, M. L., Ghatage, P., & Köbel, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030515 · Cited by 49
“, high-grade serous carcinomas frequently express estrogen receptor (ER) but are associated with an unfavorable outcome) [12].”
BackgroundSelf-citationPinton, G., Nilsson, S. V., & Moro, L. (2018) · Oncogenesis · doi:10.1038/s41389-018-0027-9 · Cited by 49
Singha, B., Harper, S. L., Goldman, A. R., Bitler, B. G., Aird, K. M., Borowsky, M. E., Cadungog, M. G., Liu, Q., Zhang, R., Jean, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32885-2 · Cited by 49
Alsiary, R., Brüning‐Richardson, A., Bond, J., Morrison, E. E., Wilkinson, N., & Bell, S. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097059 · Cited by 48
“For example, Köbel et al, 2008 [45], stated that a study of 21 candidate biomarkers for EOC revealed a varied association of biomarker expression with subtypes and they argued that each subtype within a cohort should be analyzed discretely.”
BackgroundWu, J., Yin, H., Zhu, J., Buckanovich, R. J., Thorpe, J. D., Dai, J., Urban, N. D., & Lubman, D. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121112 · Cited by 48
“Although identification of subtype specific markers for diagnosis of ovarian cancer has been addressed in several studies [30], uniform markers that can detect all major cancer subtypes are essential in broad application screening.”
BackgroundBapat, S. A., Krishnan, A., Ghanate, A. D., Kusumbe, A. P., & Kalra, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0447 · Cited by 48
TAUBE, E. T., Denkert, C., Sehouli, J., Kunze, C. A., Dietel, M., Braicu, E. I., Letsch, A., & Darb‐Esfahani, S. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.018 · Cited by 48
Current clinical application of serum biomarkers to detect ovarian cancer
Nowak, M., Janas, Ł., Stachowiak, G., Stetkiewicz, T., & Wilczyński, J. R. (2015) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2015.55887 · Cited by 48
“They also confirmed that OC is a highly heterogeneous disease, gathering four distinct histological tumor subtypes characterized not only by distinct origin, behavior and response to chemotherapy but also by different patterns of miRNA expression [40].”
BackgroundMahadevappa, A., Krishna, S. M., & Vimala, M. G. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/24350.9381 · Cited by 48
Llauradó, M., Dawson, A., Hoenisch, J., Kim, H. H., Bamford, S., Salamanca, C. M., DiMattia, G. E., Shepherd, T. G., Cremona, M., Hennessy, B. T., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0725-1 · Cited by 49
Self-citationSerum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance
Brennan, D. J., Hackethal, A., Mann, K., Mutz‐Dehbalaie, I., Fiegl, H., Marth, C., & Obermair, A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1028-0 · Cited by 48
“Human epididymis protein 4 (HE4), initially identified as one of four cDNAs highly expressed in the human epididymis [6] is a secreted protein that is overexpressed in patients with serous and endometrioid epithelial ovarian [7,8] and uterine cancers [9-11].”
BackgroundWhen Is “Type I” Ovarian Cancer Not “Type I”? Indications of an Out-Dated Dichotomy
Salazar, C., Campbell, I., & Gorringe, K. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00654 · Cited by 47
Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer
Kulbe, H., Otto, R., Darb‐Esfahani, S., Lammert, H., Abobaker, S., Welsch, G., Chekerov, R., Schäfer, R., Dragun, D., Hummel, M., et al. (2019) · Cells · doi:10.3390/cells8070713 · Cited by 47
“Since most identified tissue-based biomarkers differ significantly between subtypes [3], histology is important and has implications for biomarker studies.”
BackgroundPast, Present and Future Targets For Immunotherapy in Ovarian Cancer
Schwab, C. L., English, D. P.-G., Roque, D. M., Pasternak, M. C., & Santin, A. D. (2014) · Immunotherapy · doi:10.2217/imt.14.90 · Cited by 47
Clear Cell Carcinoma of the Female Genital Tract (Not Everything Is as Clear as it Seems)
Offman, S. L., & Longacre, T. A. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31826663b1 · Cited by 47
Page, C. L., Huntsman, D. D., Provencher, D. M., & Mes‐Masson, A. (2010) · Cancers · doi:10.3390/cancers2020913 · Cited by 46
“[16] observed a significant association of Ki67 in a cohort of patients representing several histosubtypes of the disease but no association was observed when each subtype was individually analyzed.”
InfluentialSelf-citationExpression and Function of Androgen Receptor Coactivator p44/Mep50/WDR77 in Ovarian Cancer
Ligr, M., Patwa, R. R., Daniels, G., Pan, L. Y., Wu, X., Li, Y., Tian, L., Wang, Z., Xu, R., Wu, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026250 · Cited by 46
“Genome-wide global gene analysis further defines distinct expression profiles of different types of ovarian cancer [6].”
Backgroundvan der Gun, B. T. F., de Groote, M. L., Kazemier, H. G., Arendzen, A. J., Terpstra, P., Ruiters, M. H. J., McLaughlin, P. M., & Rots, M. G. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.231 · Cited by 45
“Numerous studies confirmed the EpCAM overexpression in ovarian carcinomas (Heinzelmann-Schwarz et al, 2004; Spizzo et al, 2006; Kobel et al, 2008), turning EpCAM into a well-established ovarian tumour marker (Spizzo et al, 2011).”
BackgroundMaines‐Bandiera, S., Woo, M. M. M., Borugian, M. J., Molday, L. L., Hii, T., Gilks, C. B., Leung, P. C. K., Molday, R. S., & Auersperg, N. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181bcc96d · Cited by 45
“3Y7 One of the problems in the detection of EOC is their heterogeneity, which has led to the conclusion that EOC encompasses several forms of ovarian neoplasms with distinct origins, genetic markers, phenotypes, and clinical courses.(8,9) There is increasing evidence that this heterogeneity is reflected in the types a…”
BackgroundSelf-citationZanjirband, M., Curtin, N., Edmondson, R. J., & Lunec, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19266 · Cited by 44
“Mucinous and clear cell histological subtypes do not respond well to current chemotherapy strategies and are clinically challenging to treat [3, 4].”
Shrestha, R., Llauradó, M., Dawson, A., Hoenisch, J., Volik, S. V., Lin, Y., Anderson, S. A., Kim, H. H., Haegert, A. M., Colborne, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2222 · Cited by 45
Opportunistic salpingectomy for ovarian cancer prevention
Hanley, G. E., McAlpine, J. N., Kwon, J. S., & Mitchell, G. (2015) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-015-0014-1 · Cited by 45
“Ovarian cancer is a heterogeneous disease and itscellular origins remain an area of active debate [18, 19].”
BackgroundDuchêne, D., Colombo, É., Désilets, A., Boudreault, P., Leduc, R., Marsault, É., & Najmanovich, R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5015633 · Cited by 46
Ovarian Cancer: A Clinical Challenge That Needs Some Basic Answers
Lawrenson, K., & Gayther, S. A. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000025 · Cited by 45
“colleagues [2] tackles the issue of clino-pathological heterogeneity in epithelial ovarian cancer.”
BackgroundProteomics as a guiding tool for more effective personalized therapy
Lee, J.-M., & Kohn, E. C. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq375 · Cited by 45
“[18] have evaluated expressed proteins of 21 candidate genes by tissue microarray immunohistochemical (IHC) analysis.”
BackgroundST14 Gene Variant and Decreased Matriptase Protein Expression Predict Poor Breast Cancer Survival
Kauppinen, J. M., Kosma, V., Soini, Y., Sironen, R. K., Nissinen, M., Nykopp, T. K., Kärjä, V. J., Eskelinen, M. J., Kataja, V. V., & Mannermaa, A. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0418 · Cited by 45
Linder, N., Bützow, R. C., Lassus, H. J., Lundin, M., & Lundin, J. E. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.10.026 · Cited by 44
Different staining patterns of ovarian Brenner tumor and the associated mucinous tumor
Roma, A. A., & Masand, R. P. (2014) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2014.12.002 · Cited by 44
“Liliac et al [13] reviewed the published data on PAX8 expression of mucinous tumors that was quite variable ranging from 4% to 50% [14-19].”
BackgroundZheng, P., Li, N., & Zhan, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.972341 · Cited by 45
Specimen Quality Evaluation in Canadian Biobanks Participating in the COEUR Repository
Page, C. L., Köbel, M., de Ladurantaye, M., Rahimi, K., Madore, J., Babinszky, S., Bachvarov, D. R., Bachvarova, M., Beauchamp, M.-C., Cass, C. E., et al. (2013) · Biopreservation and Biobanking · doi:10.1089/bio.2012.0044 · Cited by 44
“Using a cut-off level of 50% of stained tumor cells as described elsewhere, 6,7 we observed that 73% of cases were positive for p53 staining (Fig.”
InfluentialSelf-citationChenevix‐Trench, G., Kelemen, L. E., Bandera, E. V., Terry, K. L., Rossing, M. A., Brinton, L. A., Doherty, J. A., Ness, R. B., Kjær, S. K., Chang-Claude, J. C., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-28 · Cited by 44
“Additionally, primary studies differ in their adjustment for important confounders, in whether they distinguish invasive cancers from borderline tumors, which differ genetically, molecularly and clinically [41,42], and in whether they reported associations separately by histologic type.”
BackgroundSelf-citationSmoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer
Kelemen, L. E., Warren, G. W., Koziak, J. M., Köbel, M., & Steed, H. L. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.11.008 · Cited by 44
“As expected [18], patients with endometrioid ovarian cancers had the best prognosis.”
ResultSelf-citationCapriglione, S., Plotti, F., Miranda, A., Ricciardi, R., Scaletta, G., Aloisi, A., Guzzo, F., Montera, R., & Angioli, R. (2015) · Tumor Biology · doi:10.1007/s13277-015-3049-3 · Cited by 43
“Human epididymis protein 4 (HE4) is a novel tumor marker that circulates in the bloodstream and is overexpressed in patients with serous and endometrioid epithelial ovarian carcinomas and recurrent ovarian cancer [24–26].”
BackgroundMa, X., Wu, Y., Zhang, T., Song, H., Jv, H., Guo, W., & Ren, G. (2017) · Journal of Cancer · doi:10.7150/jca.20935 · Cited by 43
“The proliferation rate of tumor cells varies among different subtypes of cancers [25, 26].”
BackgroundThe recent progress and therapy in endometriosis-associated ovarian cancer
Su, K., Wang, P., Yu, M.-H., Chang, C.-M., & Chang, C. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000262 · Cited by 43
Determinants of quality of life in ovarian cancer survivors: a pilot study
Teng, F. F., Kalloger, S. E., Brotto, L., & McAlpine, J. N. (2014) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30513-2 · Cited by 42
Self-citation
Metadata
- Authors
- Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., Prentice, L. M., Miller, D., Santos, J., Swenerton, K., Gilks, C. B., & Huntsman, D.
- Affiliations
- BC Cancer Agency (CA)
- Canary Foundation (US)
- Georgia Institute of Technology (US)
- Corresponding author
- Huntsman, David
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 5
- Issue
- 12
- Pages
- e232
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2592352
- OpenAlex
- W2129355295
- Cited by
- 814
- References
- 40
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 30 · 2023: 43 · 2022: 34 · 2021: 37 · 2020: 39 · 2019: 33 · 2018: 50 · 2017: 44 · 2016: 60 · 2015: 42 · 2014: 60 · 2013: 71 · 2012: 70
- FWCI
- 59.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Canary Foundation
- Michael Smith Health Research BC
- Eli Lilly Canada
- Canadian Institutes of Health Research (017051)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- ovarian carcinoma, histological subtypes, high-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, tumor markers, prognostic factors, Ki-67, WT1, CA125, HE4, stage at diagnosis, survival, molecular pathogenesis, tumor cell proliferation
- MeSH terms
- Carcinoma, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Ovarian Diseases, Ovarian Neoplasms, Prognosis, Retrospective Studies, Biomarkers, Tumor, Cohort Studies, Confounding Factors, Epidemiologic, Survival Analysis, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.